chevron_leftBack
As of 13 June 2026, Adial Pharmaceuticals, Inc. has a market cap of $2.2M USD, ranking #47000 globally and #5963 in the United States.
It ranks #4160 in the Healthcare sector, and #1318 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$2.2MUSD
Enterprise Value
-$3.65MUSD
EBITDA (TTM)
-$7.8MUSD
Net Income (TTM)
-$7.98MUSD
PB Ratio
0.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Cary Claiborne
open_in_new
Employees
5
Founded
2010
IPO
30 Jul 2018
Website
adial.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -1.9% | -6.1% | -72% | -84% | -91% |
News
Loading...
ADIL Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ADIL
ISIN: US00688A3041
Shares Out.:
Shares Outstanding:
2.144M1
Shares Float:
2.123M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.54 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
35M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
25M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
16M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
12M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
7M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
5M%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
15M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
13M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
12M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
8M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
5M%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
5M%
80.96B GBP
|
14.6
|
chevron_leftBack